vs
Side-by-side financial comparison of SeaStar Medical Holding Corp (ICU) and PULSE BIOSCIENCES, INC. (PLSE). Click either name above to swap in a different company.
SeaStar Medical Holding Corp is the larger business by last-quarter revenue ($420.0K vs $264.0K, roughly 1.6× PULSE BIOSCIENCES, INC.). SeaStar Medical Holding Corp runs the higher net margin — -691.4% vs -6603.4%, a 5912.0% gap on every dollar of revenue.
ICU Medical, Inc. is a medical technology company based in San Clemente, California. ICU Medical products are designed to prevent bloodstream infections and protect healthcare workers from exposure to infectious diseases or hazardous drugs. ICU Medical product line includes intravenous therapy (IV) products, pumps, needle-free vascular access devices, custom infusion sets, closed system hazardous drug handling devices and systems, sensor catheters, needle-free closed blood sampling systems, a...
Colossal Biosciences Inc. is an American biotechnology and genetic engineering company working to de-extinct several extinct animals, including the woolly mammoth, the Tasmanian tiger, the northern white rhinoceros, the dire wolf, the dodo, and the moa. In 2023, it stated that it wants to have woolly mammoth hybrid calves by 2028, and wants to reintroduce them to the Arctic tundra habitat. Likewise, it launched the Tasmanian Thylacine Advisory Committee, a thylacine research project to releas...
ICU vs PLSE — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $420.0K | $264.0K |
| Net Profit | $-2.9M | $-17.4M |
| Gross Margin | 97.1% | — |
| Operating Margin | -718.6% | -6914.0% |
| Net Margin | -691.4% | -6603.4% |
| Revenue YoY | 526.9% | — |
| Net Profit YoY | 34.3% | 10.1% |
| EPS (diluted) | — | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $420.0K | $264.0K | ||
| Q3 25 | $183.0K | $86.0K | ||
| Q2 25 | $338.0K | $0 | ||
| Q1 25 | $293.0K | $0 | ||
| Q4 24 | $67.0K | $0 | ||
| Q3 24 | $68.0K | $0 | ||
| Q2 24 | $0 | $0 | ||
| Q1 24 | $0 | $0 |
| Q4 25 | $-2.9M | $-17.4M | ||
| Q3 25 | $-3.5M | $-19.4M | ||
| Q2 25 | $-2.0M | $-19.2M | ||
| Q1 25 | $-3.8M | $-16.8M | ||
| Q4 24 | $-4.4M | $-19.4M | ||
| Q3 24 | $-4.5M | $-12.7M | ||
| Q2 24 | $-3.2M | $-11.4M | ||
| Q1 24 | $-12.7M | $-10.1M |
| Q4 25 | 97.1% | — | ||
| Q3 25 | 92.3% | -224.4% | ||
| Q2 25 | 92.0% | — | ||
| Q1 25 | 100.0% | — | ||
| Q4 24 | 100.0% | — | ||
| Q3 24 | 100.0% | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | -718.6% | -6914.0% | ||
| Q3 25 | -1955.7% | -23682.6% | ||
| Q2 25 | -519.5% | — | ||
| Q1 25 | -1304.4% | — | ||
| Q4 24 | -7114.9% | — | ||
| Q3 24 | -6552.9% | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | -691.4% | -6603.4% | ||
| Q3 25 | -1897.3% | -22540.7% | ||
| Q2 25 | -592.3% | — | ||
| Q1 25 | -1287.4% | — | ||
| Q4 24 | -6595.5% | — | ||
| Q3 24 | -6585.3% | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | $-0.18 | — | ||
| Q1 25 | $-0.44 | — | ||
| Q4 24 | $0.23 | — | ||
| Q3 24 | $-1.10 | — | ||
| Q2 24 | $-1.03 | — | ||
| Q1 24 | $-4.73 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $80.7M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $10.4M | $80.7M |
| Total Assets | $14.2M | $94.5M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $80.7M | ||
| Q3 25 | — | $95.2M | ||
| Q2 25 | — | $106.3M | ||
| Q1 25 | — | $119.3M | ||
| Q4 24 | — | $118.0M | ||
| Q3 24 | — | $79.0M | ||
| Q2 24 | — | $26.2M | ||
| Q1 24 | — | $34.9M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $0 | — | ||
| Q2 24 | $0 | — | ||
| Q1 24 | $1.1M | — |
| Q4 25 | $10.4M | $80.7M | ||
| Q3 25 | $11.5M | $92.7M | ||
| Q2 25 | $3.3M | $104.5M | ||
| Q1 25 | $565.0K | $118.5M | ||
| Q4 24 | $-2.2M | $114.9M | ||
| Q3 24 | $-2.1K | $79.1M | ||
| Q2 24 | $-6.9M | $27.0M | ||
| Q1 24 | $-4.5M | $36.3M |
| Q4 25 | $14.2M | $94.5M | ||
| Q3 25 | $15.5M | $108.8M | ||
| Q2 25 | $8.4M | $120.3M | ||
| Q1 25 | $7.6M | $133.4M | ||
| Q4 24 | $4.7M | $132.5M | ||
| Q3 24 | $4.6M | $93.0M | ||
| Q2 24 | $3.5M | $40.4M | ||
| Q1 24 | $7.7M | $49.2M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-4.1M | $-14.8M |
| Free Cash FlowOCF − Capex | — | $-14.9M |
| FCF MarginFCF / Revenue | — | -5628.8% |
| Capex IntensityCapex / Revenue | — | 39.8% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-54.4M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-4.1M | $-14.8M | ||
| Q3 25 | $-3.8M | $-13.0M | ||
| Q2 25 | $-3.0M | $-12.8M | ||
| Q1 25 | $-2.7M | $-13.5M | ||
| Q4 24 | $-4.7M | $-9.1M | ||
| Q3 24 | $-5.0M | $-9.0M | ||
| Q2 24 | $-2.8M | $-8.4M | ||
| Q1 24 | $-3.5M | $-9.8M |
| Q4 25 | — | $-14.9M | ||
| Q3 25 | — | $-13.1M | ||
| Q2 25 | — | $-12.9M | ||
| Q1 25 | — | $-13.6M | ||
| Q4 24 | — | $-9.2M | ||
| Q3 24 | — | $-9.1M | ||
| Q2 24 | — | $-8.4M | ||
| Q1 24 | — | $-9.8M |
| Q4 25 | — | -5628.8% | ||
| Q3 25 | — | -15233.7% | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | 39.8% | ||
| Q3 25 | — | 72.1% | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
